@article{3101162,
    title = "Balanced control of both hyper and hypo-inflammatory phases as a new treatment paradigm in sepsis",
    author = "Tsirigotis, P. and Chondropoulos, S. and Gkirkas, K. and Meletiadis, J. and Dimopoulou, I.",
    journal = "Journal of thoracic disease",
    year = "2016",
    volume = "8",
    number = "5",
    pages = "E312-E316",
    publisher = "Pioneer Bioscience Publishing",
    doi = "10.21037/jtd.2016.03.47",
    keywords = "Janus kinase;  ruxolitinib;  STAT protein, Article;  clinical effectiveness;  cytokine production;  disease activity;  disease association;  drug efficacy;  drug response;  homeostasis;  human;  hyperinflammation;  hypoinflammation;  immune response;  immunomodulation;  immunosuppressive treatment;  inflammation;  molecular pathology;  nonhuman;  outcome assessment;  patient monitoring;  sepsis;  treatment failure",
    abstract = "The immune response of the host against invading pathogens is clinically manifested as sepsis. Sepsis is a complicated process characterized by distinct phases that usually occur in a sequential manner. The initial hyper-inflammation helps in elimination of the pathogen, but potentially may lead to excessive tissue injury. Hypo-inflammation helps in restoring immune homeostasis, but may lead to significant immune suppression and death from secondary infections if not appropriately controlled. Immune-modulating intervention in sepsis should be based on a balanced control of both the hyper and the hypo-inflammatory phase. © 2016. Journal of Thoracic Disease."
}